The kind of small molecules that we’re developing are some of the first that are specifically designed for this coronavirus protease,” Pegan said. “Up till now, most therapeutic work against SARS has targeted another virulence factor, C3Lpro. This is a great start with a different target. Our hope is that we can turn this into a starting point for creating a drug that we can get in front of the US Food and Drug Administration (FDA).